This article considers different ways by which university inventors can commercialize their research and allow it to develop its full potential towards contributing to the welfare of the national and international community. It also considers some of the good and bad things relating to the various possible approaches from the inventor's perspective.
Get full access to this article
View all access options for this article.
References
1.
SkinnerG.R.B., BuchanA., DurhamJ., CowanM., DaviesJ., BrookesK. and CastrucciG., ‘Role of bovine mammillitis virus towards preparation of an alternative vaccine against herpes simplex virus infections of human subjects’, Vaccine, No 5, 1987, pp 55–9.
2.
ShariffD.HallworthJ.A.BuchanA. and SkinnerG.R.B. ‘Irreproducibility of neutralisation of herpes simplex virus under conditions where antibody is not in excess’, Intervirology, No 28, 1987, pp 100–4.
3.
SkinnerG.R.B., CowanM., DaviesJ., BrookesK., WhatmoreJ., McLeishP. and BuchanA., ‘Reduced turmorigenicity of rodent tumour cells and tumour explants following infection with wild type and mutant herpes simplex virus, bovine mammillitis and encephalomyocarditis virus’, British Journal of Experimental Pathology, No 69, 1988, pp 495–504.
